letrozole SIE
/ ROVI Pharmaceuticals Laboratories
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 11, 2026
SIE-1: A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer
(clinicaltrials.gov)
- P1 | N=120 | Not yet recruiting | Sponsor: Rovi Pharmaceuticals Laboratories
New P1 trial • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2
1 to 1
Of
1
Go to page
1